Biocartis Group NV: Disclosure of outstanding voting securities
(Thomson Reuters ONE) -
Press release - Regulated information
Mechelen, Belgium, 11 April 2016 - Biocartis Group NV (the 'Company' or
'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels:
BCART), today announces that 45,000 new shares were issued as a result of the
exercise of stock options under the 2013 Plan for employees, consultants and
management members.
In view hereof, in accordance with article 15 of the Belgian Act of 2 May 2007
on the disclosure of major shareholdings in issuers' shares of which are
admitted to trading on a regulated market and laying down miscellaneous
provisions (the 'Belgian Act'), the outstanding share capital and outstanding
voting securities of the Company can be summarised as follows:
* Total outstanding share capital: EUR 405,891.88;
* Total outstanding voting securities: 40,589,188 shares;
* Total outstanding voting rights: 40,589,188 voting rights;
* Shares that can still be issued: 5,366,935 shares (each share entailing one
voting right), of which:
* 859,172 shares can be issued upon the exercise of 859,172 outstanding
stock options (each stock option having the form of a warrant) that are
still outstanding under the '2013 Plan' for employees, consultants and
management members, entitling the holders thereof to acquire one new
share per option;
* 262,934 shares can be issued upon the exercise of 262,934 outstanding
stock options (each stock option having the form of a warrant) that are
still outstanding under the '2015 Plan' for employees, consultants,
management members and directors, entitling the holders thereof to
acquire one new share per option;
* 67,000 shares can be issued upon the exercise of 67,000 warrants, called
'WHC Warrants', granted to Whitemarsh Capital LLC, a commercial partner
of Biocartis, with each warrant exercisable into one share;
* 4,177,829 shares can be issued pursuant to a conversion option agreement
entered into between Koninklijke Philips N.V. ('Philips') and the
Company[1].
[1] The conversion option agreement allows Philips to convert certain royalty
and other payments due to it up to a maximum of 10% of the then outstanding
capital of the Company on a fully diluted post-money basis, but only if the
Company has not yet made a lump sum payment in lieu of such royalty and other
payments, and the conversion can only be exercised by Philips upon the
acceptance of the exercise by the Company at its sole discretion. The number of
4,177,829 shares that can still be issued assumes that all outstanding warrants
(entailing the issue of up to 1,189,106 new shares) have been exercised, it
being understood that the actual number of shares issuable depends on a number
of factors.
Pursuant to the Belgian Act and the articles of association of the Company, a
notification to the Company and the Belgian Financial Services and Markets
Authority (FSMA) is required by all natural and legal persons in each case where
the percentage of voting rights attached to the securities held by such persons
in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and
every subsequent multiple of 5%, of the total number of voting rights in the
Company.
----- END ----
More information:
Biocartis
Renate Degrave
Corporate Communications and Investor Relations
+32 15 631 729
press(at)biocartis.com
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at improving
clinical practice for the benefit of patients, clinicians, payers and industry.
Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-
result, real-time PCR (Polymerase Chain Reaction) system that offers accurate,
highly reliable molecular information from virtually any biological sample in
virtually any setting. Idylla(TM) addresses the growing demand for personalized
medicine by allowing fast and effective treatment selection and treatment
progress monitoring. Biocartis launched the Idylla(TM) platform in September
2014. Biocartis is developing and marketing a rapidly expanding test menu
addressing key unmet clinical needs in oncology and infectious diseases. These
areas represent respectively the fastest growing and largest segments of the MDx
market worldwide. Today, Biocartis has four oncology tests and one test for
infectious diseases on the market. More information: www.biocartis.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biocartis Group NV via GlobeNewswire
[HUG#2002058]
Unternehmensinformation / Kurzprofil:
Datum: 11.04.2016 - 17:31 Uhr
Sprache: Deutsch
News-ID 463168
Anzahl Zeichen: 5766
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 281 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biocartis Group NV: Disclosure of outstanding voting securities"
steht unter der journalistisch-redaktionellen Verantwortung von
Biocartis Group NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
